Cardinal Health (NYSE: CAH) is a healthcare distribution company that wholesales branded and generic pharmaceuticals, over-the-counter healthcare products, medical devices, and surgical products to hospitals, retail pharmacies, and other healthcare providers across the United States. Revenue comes primarily from product distribution margins in two segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). Cardinal Health competes directly with McKesson Corporation and Cencora, Inc. in pharmaceutical wholesale, and with Medline Industries and Owens & Minor in medical products distribution. The company also operates specialty businesses serving oncology, rheumatology, urology, nephrology, and gastroenterology, supported by recent acquisitions including ION ($1.1B, December 2024), Specialty Networks ($1.2B, March 2024), GIA ($2.8B, January 2025), and ADS ($1.1B, April 2025). Cardinal Health carries $8.3B in total debt obligations and faces $4.8B in remaining opioid litigation settlement payments as disclosed in the FY2025 10-K filed August 12, 2025.

Revenue model

Transactional distribution margins on branded and generic pharmaceuticals, medical devices, and surgical products sold to hospitals, retail pharmacy chains, independent drug stores, and other healthcare providers. Additional fee-based revenue from services to pharmaceutical manufacturers including inventory management, data reporting, new product launch support, and chargeback administration. Specialty segment revenue from consulting, patient support, logistics, and group purchasing services. Management services organization revenue from physician practice support across oncology, gastroenterology, and urology.

Products and services

Branded and generic pharmaceutical distribution; over-the-counter healthcare and consumer product distribution; specialty pharmaceuticals covering oncology, rheumatology, urology, nephrology; human-derived plasma products; medical devices and surgical products; pharmacy management services; nuclear radiopharmacy operations; generic pharmaceutical repackaging; physician practice management services through Navista (oncology), GIA (gastroenterology), and Urology America; diabetes medical supply distribution via ADS; generic pharmaceutical sourcing through Red Oak Sourcing joint venture with CVS Health (through June 2029).

Customers and end markets

Chain and independent drug stores; pharmacy departments of supermarkets and mass merchandisers; hospitals; specialty pharmacies; dialysis clinics; physician offices; community health centers; independent community oncology practices; gastroenterology and urology management services organizations. End markets include retail pharmacy, acute care, specialty care, and home health (diabetes supplies via ADS).

Value-chain role

Wholesale distributor and logistics intermediary sitting between pharmaceutical and medical product manufacturers and end-point healthcare providers. Maintains prime vendor relationships to consolidate purchasing for retail and hospital customers. Also acts as a services provider to manufacturers (distribution, data, launch support) and a management services organization operator for independent physician practices.

Geographic exposure

Primary operations in the United States. ION supports more than 50 practice sites across 10 states as of the FY2025 10-K filed August 12, 2025. Geographic mix beyond the U.S. is not specified in the filing excerpts provided.

Competitors

McKesson Corporation, Cencora, Inc., Medline Industries, Inc., Owens & Minor, Inc., Regional wholesale distributors, Self-warehousing pharmacy chains, Specialty distributors, Third-party logistics companies, Regional medical product distributors

Source: SEC 10-K, filed 2025-08-12

Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Peers: Adapthealth Corp Cencora Inc COVETRUS, INC. Henry Schein Inc McKesson Corp PATTERSON COMPANIES, INC. Accendra Health Inc PetIQ, Inc.